Navigation Links
Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
Date:3/25/2009

CARLSBAD, Calif., March 25 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Citi's 4th Annual Biotech Day on Wednesday, April 1, 2009, at 2:00 p.m. ET at the 388 Greenwich Street Conference Center in New York, NY.

A live audio webcast of the presentation will be available on the "Investor Center" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
2. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
3. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
4. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
5. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
6. Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
7. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
9. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
11. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Calabasas, CA (PRWEB) July 24, 2014 ... advancing the Global Supply Chain of the biotech ... annual SCM Innovation Awards, brought to you by ... premiere global organization of supply chain management professionals ... be given to stakeholders of the Biotech industry ...
(Date:7/24/2014)... Security forces worldwide rely on sophisticated equipment, trained ... other public areas against terrorist attacks. A revolutionary ... about to make their job much easier. , ... Patolsky of Tel Aviv University ,s School of ... developed by the Herzliya company Tracense, picks up ...
(Date:7/24/2014)... natural and synthetic processes prefer to settle into ... energyit is within the realm of non-equilibrium conditions ... changes in energy and phases, such as temperature ... allow humans to regulate their body temperature, airplanes ... seismic activity. , But even though these ...
(Date:7/24/2014)... , July 24, 2014 SRI International ... with the National Institute of Allergy and Infectious Diseases ... conduct preclinical development of potential therapies for HIV infection ... to treat HIV and AIDS and the complications and ... microbicides for preventing sexual transmission of HIV. ...
Breaking Biology Technology:Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... Oct. 20 Prometheus Research LLC has formed the ... including dashboards and reports. The group will draw on ... of building custom biomedical data management applications. ... said Andrzej Pienczykowski, Executive Vice President for Product Development ...
... Incorporated (NYSE: DGX ), the world,s leading ... its Board of Directors increased the company,s share repurchase ... first three quarters of 2010, the company repurchased approximately ... fully utilizing its previous authorization, which was granted in ...
... OAK RIDGE, Tenn., Oct. 19, 2010 -- The Cold ... National Laboratory,s High Flux Isotope Reactor and a complementary ... entered its commissioning phase. The CTAX uses "cold" ... magnetic excitations in materials. Cold neutrons are slower than ...
Cached Biology Technology:Prometheus Research Launches Solutions Group to Springboard HTSQL-based Solutions for Customers 2ORNL's research reactor revamps veteran neutron scattering tool 2
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... on different species of fish, according to a ... Exeter which tested fish anti-predator behaviour. , ... predator model when exposed to additional noise, whereas ... , Lead author Dr Irene Voellmy of Bristol,s ... many aquatic environments have increased substantially during the ...
(Date:7/24/2014)... its own microbial terroir, meaning the microbial populations found ... the product, creating the final flavor according to research ... and Environmental Microbiology . This is the first time ... brewery. , Many sake makers inoculate with both ... of the University of California, Davis, but he and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4The microbes make the sake brewery 2
... Researchers at Oregon State University have helped sequence ... for genetic improvements to related fruits like apples, peaches ... the journal Nature Genetics . "This will ... commercial strawberries," said OSU plant molecular biologist Todd Mockler, ...
... international research consortium has sequenced the genome of the ... Dec. 26 advance online edition of the journal ... possibilities for breeding tastier, hardier varieties of the berry ... the strawberry parts list," said the consortium,s leader Kevin ...
... brain tumours in larvae of the fruit fly Drosophila ... grow. The removal of some of these genes leads to ... for tumour development. The study, headed by ICREA researcher Cayetano ... . One of the characteristics of tumour cells ...
Cached Biology News:OSU helps decode strawberry genome in bid to improve fruit 2OSU helps decode strawberry genome in bid to improve fruit 3Georgia Tech team helps decode newly sequenced strawberry genome 2Georgia Tech team helps decode newly sequenced strawberry genome 3Some brain tumors mimic the genetic program of germline cells 2
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....
Recombinant Rat Leptin, CF...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: